Baxter International Reports Mixed Q4 Results and Outlook

Baxter International ( (BAX) ) has provided an update.

Baxter International reported on Feb. 12, 2026, that fourth-quarter 2025 sales from continuing operations rose 8% to $2.97 billion on a reported basis, though adjusted diluted EPS from continuing operations fell 24% to $0.44, and GAAP results showed a $1.04 billion loss driven by goodwill impairment and a large tax valuation allowance. Segment performance was mixed, with solid growth across Medical Products & Therapies, Healthcare Systems & Technologies and Pharmaceuticals, supported by new product launches and hospital connectivity initiatives, while management cautioned that 2026 sales from continuing operations are expected to be roughly flat and guided adjusted EPS to $1.85–$2.05, signaling a focus on operational improvement after the Kidney Care divestiture.

As part of a broader board refresh announced alongside earnings, Baxter appointed veteran finance executive Michael R. McDonnell to its board and Audit Committee effective Feb. 13, 2026, while directors Cathy R. Smith and Stephen H. Rusckowski resigned the same day, reducing the board to 10 members and shifting Nominating Committee leadership to Patricia B. Morrison. The board on Feb. 11, 2026, also declared a quarterly cash dividend of $0.01 per share payable April 1, 2026, actions that collectively underscore a period of governance transition and disciplined capital management as the company works to improve execution and reinforce its long-term trajectory.

The most recent analyst rating on (BAX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Baxter International stock, see the BAX Stock Forecast page.

Spark’s Take on BAX Stock

According to Spark, TipRanks’ AI Analyst, BAX is a Neutral.

The score is primarily held back by weak financial performance—losses, high leverage, and sharply worse free cash flow—supported only modestly by a neutral-to-soft technical setup. Guidance and recent debt-management actions add some stability, but operational headwinds (notably the infusion pump issue) and loss-based valuation limit the overall score.

To see Spark’s full report on BAX stock, click here.

More about Baxter International

Baxter International Inc., based in Deerfield, Ill., is a global medtech leader providing connected solutions, medical devices and advanced injectable technologies for hospitals, physicians’ offices and other care settings. With roughly 37,500 employees, the company focuses on essential therapies and technologies that support its long-standing mission to save and sustain lives worldwide.

Average Trading Volume: 8,461,567

Technical Sentiment Signal: Sell

Current Market Cap: $11.28B

For an in-depth examination of BAX stock, go to TipRanks’ Overview page.